OBJECTIVES: Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a cardiac disease characterised by myocardial necrosis followed by fibro-fatty substitution leading to the onset of ventricular arrhythmias. The aim of the present study was to analyse pregnancy in women affected by this condition. STUDY DESIGN: Six women affected by ARVC/D who underwent a pregnancy were studied with a follow-up programme, consisting of 12-lead ECG, signal-averaged ECG, 24-h ECG and two-dimensional and Doppler echocardiogram performed before the beginning of the pregnancy, at 3rd and 7th month of gestation and after the delivery. RESULTS: All women were on antiarrhythmic therapy during pregnancy; two complained of palpitations in the last 3 months. Delivery was performed at full terms in all, with caesarean section and epidural anaesthesia in four. Mean weight at birth was 3490g. No adverse reactions on the newborns were detected. All patients were advised against breast-feeding. No significant morphological changes were detected. During the period following the delivery (1-6years, mean 2,6years) one subject experienced a sustained ventricular tachycardia. CONCLUSIONS: Pregnancy seems to be well tolerated in patients affected by ARVC/D, but a programmed clinical protocol is mandatory particularly in the last trimester and puerperium, due to increased risk of ventricular arrhythmias.
OBJECTIVES:Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a cardiac disease characterised by myocardial necrosis followed by fibro-fatty substitution leading to the onset of ventricular arrhythmias. The aim of the present study was to analyse pregnancy in women affected by this condition. STUDY DESIGN: Six women affected by ARVC/D who underwent a pregnancy were studied with a follow-up programme, consisting of 12-lead ECG, signal-averaged ECG, 24-h ECG and two-dimensional and Doppler echocardiogram performed before the beginning of the pregnancy, at 3rd and 7th month of gestation and after the delivery. RESULTS: All women were on antiarrhythmic therapy during pregnancy; two complained of palpitations in the last 3 months. Delivery was performed at full terms in all, with caesarean section and epidural anaesthesia in four. Mean weight at birth was 3490g. No adverse reactions on the newborns were detected. All patients were advised against breast-feeding. No significant morphological changes were detected. During the period following the delivery (1-6years, mean 2,6years) one subject experienced a sustained ventricular tachycardia. CONCLUSIONS: Pregnancy seems to be well tolerated in patients affected by ARVC/D, but a programmed clinical protocol is mandatory particularly in the last trimester and puerperium, due to increased risk of ventricular arrhythmias.
Authors: Ana Morales; Dawn C Allain; Patricia Arscott; Emily James; Gretchen MacCarrick; Brittney Murray; Crystal Tichnell; Amy R Shikany; Sara Spencer; Sara M Fitzgerald-Butt; Jessica D Kushner; Christi Munn; Emily Smith; Katherine G Spoonamore; Harikrishna S Tandri; W Aaron Kay Journal: J Genet Couns Date: 2017-03-10 Impact factor: 2.537
Authors: Anke R Hodes; Crystal Tichnell; Anneline S J M Te Riele; Brittney Murray; Judith A Groeneweg; Abhishek C Sawant; Stuart D Russell; Karin Y van Spaendonck-Zwarts; Maarten P van den Berg; Arthur A Wilde; Harikrishna Tandri; Daniel P Judge; Richard N W Hauer; Hugh Calkins; J Peter van Tintelen; Cynthia A James Journal: Heart Date: 2015-12-30 Impact factor: 5.994
Authors: Kristina H Haugaa; Henning Bundgaard; Thor Edvardsen; Ole Eschen; Thomas Gilljam; Jim Hansen; Henrik Kjærulf Jensen; Pyotr G Platonov; Anneli Svensson; Jesper H Svendsen Journal: Scand Cardiovasc J Date: 2015-09-23 Impact factor: 1.589